Olema Pharmaceuticals (OLMA) vs Verastem (VSTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Verastem (VSTM) has outperformed Olema Pharmaceuticals (OLMA) over the past year, losing 9.3% versus a loss of 27.1%. Over five years, OLMA leads with a -74.5% price change compared with -75.5% for VSTM. Verastem is the larger company by market cap ($758.9 million vs $684.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OLMA | VSTM |
|---|---|---|
| Share price | $7.82 | $8.38 |
| Market cap | $684.23M | $758.92M |
| 1-day change | 0.00% | +3.33% |
| YTD return | -68.72% | +5.05% |
| 1-year return | -27.12% | -9.28% |
| 5-year return | -74.54% | -75.51% |
| EPS (TTM) | $-2.12 | $-2.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $36.26 | $10.82 |
| 52-week low | $6.65 | $3.43 |
| Distance from 52-week high | -78.43% | -22.55% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +366.75% | +79.00% |
| Average volume | 1.06M | 2.25M |
| Shares outstanding | 87.50M | 90.56M |
| Employees | 150 | 102 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VSTM has outperformed OLMA by 17.8 percentage points over the past year.
About Olema Pharmaceuticals
OLMA stock →Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 150 employees
About Verastem
VSTM stock →Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
OLMA vs VSTM FAQ
Which is bigger, Olema Pharmaceuticals or Verastem?
Verastem (VSTM) is larger, with a market capitalization of $758.92M compared with $684.23M for Olema Pharmaceuticals (OLMA).
Which stock has performed better over the past year, OLMA or VSTM?
VSTM returned -9.28% over the past 12 months, compared with -27.12% for OLMA (price return, excluding dividends). Past performance does not predict future results.
Are Olema Pharmaceuticals and Verastem in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.